Eisai launches startup incubator for genomics-driven dementia research

The U.S. branch of Japanese pharmaceutical company Eisai announced July 9 the establishment of a new research facility dedicated to drug discovery for dementia treatment.

The Eisai Center for Genetics Guided Dementia Discovery, or G2D2, will be located in Cambridge, Mass. Research at the center will focus on using insights from genomic and other data to look for novel immunotherapy treatments beyond the traditional amyloid beta- and tau-based drugs used to treat dementia.

The center will also house several new internship and training programs and the company's first incubator program. The Eisai Incubator for NeuroDiscovery will provide research space and guidance to Cambridge-based startup and spinout biotech companies attempting to create breakthrough neuroscience treatments.

More articles about health IT:
Atrium Health integrates app for virtual pregnancy care
Tanner Health begins Epic EHR rollout: 4 things to know
Georgia hospitals partner with Allscripts' CarePort Health on care coordination tools

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.


Featured Webinars

Featured Whitepapers